Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.

Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.

Ann Oncol. 2019 Aug 27. pii: mdz291. doi: 10.1093/annonc/mdz291. [Epub ahead of print]

PMID:
31504139
2.

Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.

Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N.

Cancer J. 2019 Jul/Aug;25(4):296-299. doi: 10.1097/PPO.0000000000000392.

PMID:
31335394
3.

Circulating Tumor DNA Assays in Clinical Cancer Research.

Ossandon MR, Agrawal L, Bernhard EJ, Conley BA, Dey SM, Divi RL, Guan P, Lively TG, McKee TC, Sorg BS, Tricoli JV.

J Natl Cancer Inst. 2018 Sep 1;110(9):929-934. doi: 10.1093/jnci/djy105. Review.

4.

A mutational comparison of adult and adolescent and young adult (AYA) colon cancer.

Tricoli JV, Boardman LA, Patidar R, Sindiri S, Jang JS, Walsh WD, McGregor PM 3rd, Camalier CE, Mehaffey MG, Furman WL, Bahrami A, Williams PM, Lih CJ, Conley BA, Khan J.

Cancer. 2018 Mar 1;124(5):1070-1082. doi: 10.1002/cncr.31136. Epub 2017 Nov 30.

5.

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.

Speranza G, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshow JH, Kummar S.

Invest New Drugs. 2018 Apr;36(2):230-239. doi: 10.1007/s10637-017-0495-3. Epub 2017 Aug 12.

6.

Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.

Kim KY, Le QT, Yom SS, Ng RHW, Chan KCA, Bratman SV, Welch JJ, Divi RL, Petryshyn RA, Conley BA.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):996-1001. doi: 10.1016/j.ijrobp.2017.03.018. Epub 2017 Mar 18. Review.

PMID:
28721913
7.

Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer.

Kim KY, Le QT, Yom SS, Pinsky BA, Bratman SV, Ng RH, El Mubarak HS, Chan KC, Sander M, Conley BA.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djx007.

8.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM.

J Mol Diagn. 2017 Mar;19(2):313-327. doi: 10.1016/j.jmoldx.2016.10.007. Epub 2017 Feb 7.

9.

Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next-Generation Sequencing Assays.

Sims DJ, Harrington RD, Polley EC, Forbes TD, Mehaffey MG, McGregor PM 3rd, Camalier CE, Harper KN, Bouk CH, Das B, Conley BA, Doroshow JH, Williams PM, Lih CJ.

J Mol Diagn. 2016 May;18(3):336-349. doi: 10.1016/j.jmoldx.2015.11.008.

10.

Clinical Application of Liquid Biopsies.

Williams PM, Conley BA.

JAMA Oncol. 2016 Aug 1;2(8):1003-5. doi: 10.1001/jamaoncol.2016.0240. No abstract available.

PMID:
27054513
11.

Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, Chen AP, Kummar S, Doroshow JH, Williams PM.

J Mol Diagn. 2016 Jan;18(1):51-67. doi: 10.1016/j.jmoldx.2015.07.006. Epub 2015 Nov 18.

12.

Next-Generation Sequencing to Guide Clinical Trials.

Siu LL, Conley BA, Boerner S, LoRusso PM.

Clin Cancer Res. 2015 Oct 15;21(20):4536-44. doi: 10.1158/1078-0432.CCR-14-3215. Review.

13.

Genomically guided cancer treatments: from "promising" to "clinically useful".

Conley BA.

J Natl Cancer Inst. 2015 May 28;107(7). pii: djv168. doi: 10.1093/jnci/djv168. Print 2015 Jul. No abstract available.

PMID:
26023091
14.

GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials.

Zhao Y, Polley EC, Li MC, Lih CJ, Palmisano A, Sims DJ, Rubinstein LV, Conley BA, Chen AP, Williams PM, Kummar S, Doroshow JH, Simon RM.

Cancer Inform. 2015 Mar 19;14(Suppl 2):45-55. doi: 10.4137/CIN.S17282. eCollection 2015. Review.

15.

Application of molecular profiling in clinical trials for advanced metastatic cancers.

Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, Zhao Y, Simon RM, Conley BA, Doroshow JH.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv003. doi: 10.1093/jnci/djv003. Print 2015 Apr.

16.

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.

Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.

Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.

17.

AHNAK2 Participates in the Stress-Induced Nonclassical FGF1 Secretion Pathway.

Kirov A, Kacer D, Conley BA, Vary CP, Prudovsky I.

J Cell Biochem. 2015 Aug;116(8):1522-31. doi: 10.1002/jcb.25047.

18.

Designing biomarker studies for head and neck cancer.

Kim KY, McShane LM, Conley BA.

Head Neck. 2014 Jul;36(7):1069-75. Review.

19.

Molecular analysis for therapy choice: NCI MATCH.

Conley BA, Doroshow JH.

Semin Oncol. 2014 Jun;41(3):297-9. doi: 10.1053/j.seminoncol.2014.05.002. Epub 2014 May 22. No abstract available.

PMID:
25023344
20.

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

BMC Med. 2013 Oct 17;11:220. doi: 10.1186/1741-7015-11-220.

21.

Statistical and practical considerations for clinical evaluation of predictive biomarkers.

Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM.

J Natl Cancer Inst. 2013 Nov 20;105(22):1677-83. doi: 10.1093/jnci/djt282. Epub 2013 Oct 17.

22.

Criteria for the use of omics-based predictors in clinical trials.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

Nature. 2013 Oct 17;502(7471):317-20. doi: 10.1038/nature12564.

23.

Rare case of hairy cell leukemia with brain parenchymal involvement: a diagnostic dilemma.

Chandana SR, Kotecha R, Al-Janadi A, Chang HT, Conley BA.

J Clin Oncol. 2013 Apr 10;31(11):e186-8. doi: 10.1200/JCO.2012.44.8787. Epub 2013 Feb 25. No abstract available.

PMID:
23439755
24.

Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.

Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB.

J Thorac Oncol. 2012 Oct;7(10):1618-21.

25.

Development and use of integral assays in clinical trials.

Schilsky RL, Doroshow JH, Leblanc M, Conley BA.

Clin Cancer Res. 2012 Mar 15;18(6):1540-6. doi: 10.1158/1078-0432.CCR-11-2202.

26.

Bridging the gap: moving predictive and prognostic assays from research to clinical use.

Williams PM, Lively TG, Jessup JM, Conley BA.

Clin Cancer Res. 2012 Mar 15;18(6):1531-9. doi: 10.1158/1078-0432.CCR-11-2203.

27.

An unusual case of autoimmune pancreatitis presenting as pancreatic mass and obstructive jaundice: a case report and review of the literature.

Efeovbokhan N, Makol A, Cuison RV, Minter RM, Kotaru VP, Conley BA, Chandana SR.

J Med Case Rep. 2011 Jun 29;5:253. doi: 10.1186/1752-1947-5-253.

28.

Endoglin regulates cancer-stromal cell interactions in prostate tumors.

Romero D, O'Neill C, Terzic A, Contois L, Young K, Conley BA, Bergan RC, Brooks PC, Vary CP.

Cancer Res. 2011 May 15;71(10):3482-93. doi: 10.1158/0008-5472.CAN-10-2665. Epub 2011 Mar 28. Erratum in: Cancer Res. 2012 Feb 15;72(4):1037.

29.

Unusual presentation of large-cell poorly differentiated neuroendocrine carcinoma of the epiglottis.

Patel KJ, Chandana SR, Wiese DA, Olsen B, Conley BA.

J Clin Oncol. 2010 Sep 20;28(27):e461-3. doi: 10.1200/JCO.2010.28.6237. Epub 2010 Aug 2. No abstract available.

PMID:
20679623
30.

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.

Eur J Cancer. 2010 Jan;46(2):340-7. doi: 10.1016/j.ejca.2009.10.026. Epub 2009 Nov 27.

31.

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.

Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J, Sausville EA, Conley BA, Murgo AJ, Doroshow JH.

Cancer Chemother Pharmacol. 2010 Jan;65(2):383-9. doi: 10.1007/s00280-009-1154-y. Epub 2009 Nov 6.

32.

Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.

Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, Vary CP.

Carcinogenesis. 2010 Mar;31(3):359-66. doi: 10.1093/carcin/bgp217. Epub 2009 Sep 7.

33.

Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis.

Mancini ML, Terzic A, Conley BA, Oxburgh LH, Nicola T, Vary CP.

Dev Dyn. 2009 Oct;238(10):2479-93. doi: 10.1002/dvdy.22066.

34.
35.

Histone deacetylation : an attractive target for cancer therapy?

Al-Janadi A, Chandana SR, Conley BA.

Drugs R D. 2008;9(6):369-83. doi: 10.2165/0126839-200809060-00003. Review.

PMID:
18989989
36.

Salivary gland cancers: current treatments, molecular characteristics and new therapies.

Chandana SR, Conley BA.

Expert Rev Anticancer Ther. 2008 Apr;8(4):645-52. doi: 10.1586/14737140.8.4.645. Review.

PMID:
18402531
37.

Novel biochemical pathways of endoglin in vascular cell physiology.

Bernabeu C, Conley BA, Vary CP.

J Cell Biochem. 2007 Dec 15;102(6):1375-88. Review.

38.

Endoglin is required for myogenic differentiation potential of neural crest stem cells.

Mancini ML, Verdi JM, Conley BA, Nicola T, Spicer DB, Oxburgh LH, Vary CP.

Dev Biol. 2007 Aug 15;308(2):520-33. Epub 2007 Jun 16.

39.

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N.

J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30.

PMID:
17470851
40.

Targeting epigenetic abnormalities with histone deacetylase inhibitors.

Conley BA, Wright JJ, Kummar S.

Cancer. 2006 Aug 15;107(4):832-40. Review.

41.

Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors.

Koleva RI, Conley BA, Romero D, Riley KS, Marto JA, Lux A, Vary CP.

J Biol Chem. 2006 Sep 1;281(35):25110-23. Epub 2006 Jun 19.

42.

Treatment of advanced head and neck cancer: what lessons have we learned?

Conley BA.

J Clin Oncol. 2006 Mar 1;24(7):1023-5. No abstract available.

PMID:
16505419
43.

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.

Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, Figg WD.

Cancer Chemother Pharmacol. 2006 Feb;57(3):275-81. Epub 2005 Jul 19.

PMID:
16028097
44.

Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12. Epub 2005 Jul 11.

PMID:
16005577
45.

Clinical trial designs for predictive marker validation in cancer treatment trials.

Sargent DJ, Conley BA, Allegra C, Collette L.

J Clin Oncol. 2005 Mar 20;23(9):2020-7. Review.

PMID:
15774793
46.

Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration.

Lindner V, Wang Q, Conley BA, Friesel RE, Vary CP.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):77-83. Epub 2004 Oct 28. Erratum in: Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):e49.

PMID:
15514205
47.

Prognostic and predictive markers in cancer.

Conley BA, Taube SE.

Dis Markers. 2004;20(2):35-43. Review.

48.

Detection of prostate cancer and predicting progression: current and future diagnostic markers.

Tricoli JV, Schoenfeldt M, Conley BA.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3943-53. Review.

49.

Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain.

Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabéu C, Vary CP.

J Biol Chem. 2004 Jun 25;279(26):27440-9. Epub 2004 Apr 14.

50.

Clinical trials referral resource. Targeted therapy in squamous cell cancers of the head and neck.

Conley BA, Enos RA, Cheson BD.

Oncology (Williston Park). 2002 May;16(5):621-2, 625-6. No abstract available.

Supplemental Content

Loading ...
Support Center